NEW YORK--(BUSINESS WIRE)--Replicor Inc., a privately held biopharmaceutical company targeting a cure for chronic hepatitis B and D patients, today announced that the preliminary interim analysis from its latest REP 401 clinical trial has been selected by the American Association for the Study of Liver Disease (AASLD) for presentation during the late-breaking oral abstract session at its annual meeting to be held November 11-15, 2016 in Boston, U.S.A.
The REP 401 protocol (NCT02565719) is a randomized, controlled trial assessing the safety and efficacy of its first in class HBsAg release inhibitor, REP 2139 and a REP 2139 derivative with improved plasma and tissue clearance (REP 2165) in combination with tenofovir disoproxil fumarate (TDF) and pegylated interferon alpha 2a (peg-IFN) in treatment naïve patients with chronic HBeAg negative HBV infection. The selection of Replicor’s clinical data for presentation during the late breaking oral abstract session on November 15th, 2016 highlights the recognition of NAP-based therapy as an important new approach for achieving functional cure in patients with chronic HBV.
Complete 6 month follow-up data from the REP 301 protocol (NCT02233075) assessing the safety and efficacy of REP 2139 in combination with peg-IFN in patients with chronic HBV / HDV co-infection will also be presented during the poster session on November 14th, 2016.
These presentations will expand on the existing clinical data demonstrating the unique ability of NAP-based combination therapy to eliminate serum HBsAg and to achieve functional cure in patients with HBV and HBV / HDV co-infection.
Replicor’s presentations from AASLD 2016 will be available on the company’s website following their disclosure at the meeting at www.replicor.com/science/conference-presentations. For further information about the 2016 AASLD Meeting visit: http://www.aasld.org/events-professional-development/liver-meeting.
Replicor is a privately held biopharmaceutical company with the most advanced animal and human clinical data in the development of the cure for HBV and HDV. The company is dedicated to accelerating the development of an effective treatment for patients with HBV and HBV/HDV co-infection. For further information about Replicor please visit our website at www.replicor.com.